Literature DB >> 8017565

Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and immunocytochemical study with special reference to neuroendocrine differentiation.

L Scopsi1, S Andreola, S Pilotti, R Bufalino, M T Baldini, A Testori, F Rilke.   

Abstract

We studied the clinical, histologic, histochemical, and immunocytochemical characteristics of 61 mucinous tumors (38 pure, 23 mixed) retrieved from a consecutive series of 1,689 infiltrating carcinomas of the female breast. The only statistically significant predictors of favorable survival were histologic (pure) type coupled with the absence of axillary lymph node metastases. Other factors, including classification into A and B types according to Capella et al., and neuroendocrine status, as assessed by the presence of argyrophilia, granins, neuron-specific enolase (NSE), and synaptophysin (SYN),-all had no influence on survival. Argyrophilic cells were found in 16 pure mucinous tumors (42%) and in the mucinous component of four mixed tumors (17%). Granin (chromogranin A or B), NSE, and SYN immunoreactivities were demonstrated in all the argyrophilic tumors. We also found NSE- and SYN-immunoreactive cells in 31 of 41 and 16 of 41 nonargyrophilic (granin-unreactive) mucinous tumors, which supports the view that mucinous carcinomas of the breast as a whole are neuroendocrine-programmed tumors.

Entities:  

Mesh:

Year:  1994        PMID: 8017565

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  19 in total

1.  Neuroendocrine carcinoma of the breast with a mucinous carcinoma component: A case report with review of the literature.

Authors:  Mitsuaki Ishida; Tomoko Umeda; Hajime Abe; Tohru Tani; Hidetoshi Okabe
Journal:  Oncol Lett       Date:  2012-04-12       Impact factor: 2.967

Review 2.  Endo/exo-proteolysis in neoplastic progression and metastasis.

Authors:  Abdel-Majid Khatib; Daniel Bassi; Geraldine Siegfried; Andres J P Klein-Szanto; L'Houcine Ouafik
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

3.  Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified.

Authors:  Seho Park; Jaseung Koo; Joo-Hee Kim; Woo Ick Yang; Byeong-Woo Park; Kyong Sik Lee
Journal:  J Korean Med Sci       Date:  2010-02-19       Impact factor: 2.153

4.  Mucinous Cystadenocarcinoma of the Breast with Estrogen Receptor Expression: A Case Report and Review of the Literature.

Authors:  Sema Rakıcı; Güzin Gönüllü; S Bilge Gürsel; Levent Yıldız; I Koray Bayrak; Idris Yücel
Journal:  Case Rep Oncol       Date:  2009-11-14

5.  Mucinous Breast Cancer: a Review Study of 5 Year Experience from a Hospital-Based Series of Cases.

Authors:  Adrian Dumitru; Alexandru Procop; Andreea Iliesiu; Mircea Tampa; Luminita Mitrache; Mariana Costache; Maria Sajin; Anca Lazaroiu; Monica Cirstoiu
Journal:  Maedica (Buchar)       Date:  2015-03

6.  Clinicopathological characteristics and prognosis of mucinous breast carcinoma.

Authors:  Ming Zhang; Xiao-Dan Teng; Xin-Xin Guo; Ji-Shuang Zhao; Zhi-Gao Li
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-05       Impact factor: 4.553

7.  Mucinous carcinoma of breast: Cytodiagnosis of a case.

Authors:  Sangeeta Sharma; Rani Bansal; Anjali Khare; Nivesh Agrawal
Journal:  J Cytol       Date:  2011-01       Impact factor: 1.000

8.  Comparison of Clinical Features and Treatment Results of Mix Mucinous Carcinomas and Other Atypical Carcinomas of the Breast.

Authors:  Mustafa Gök; Uğur Topal; Bahadır Öz; Hülya Akgün; Alper Celal Akcan; Erdoğan Mütevelli Sözüer
Journal:  Eur J Breast Health       Date:  2019-10-01

Review 9.  Histology of Luminal Breast Cancer.

Authors:  Ramona Erber; Arndt Hartmann
Journal:  Breast Care (Basel)       Date:  2020-07-15       Impact factor: 2.860

10.  MicroRNA and histopathological characterization of pure mucinous breast carcinoma.

Authors:  Feng Zhou; Shuai Li; Hui-Min Meng; Li-Qiang Qi; Lin Gu
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.